Display options
Cite
Beitzen-Heineke A, Berenbrok N, Waizenegger J, et al. AXL Inhibition Represents a Novel Therapeutic Approach in . Hemasphere. 2021;5(9):e630doi: 10.1097/HS9.0000000000000630.
Beitzen-Heineke, A., Berenbrok, N., Waizenegger, J., Paesler, S., Gensch, V., Udonta, F., Vargas Delgado, M. E., Engelmann, J., Hoffmann, F., Schafhausen, P., von Amsberg, G., Riecken, K., Beumer, N., Imbusch, C. D., Lorens, J., Fischer, T., Pantel, K., Bokemeyer, C., Ben-Batalla, I., & Loges, S. (2021). AXL Inhibition Represents a Novel Therapeutic Approach in . HemaSphere, 5(9), e630. https://doi.org/10.1097/HS9.0000000000000630
Beitzen-Heineke, Antonia, et al. "AXL Inhibition Represents a Novel Therapeutic Approach in ." HemaSphere vol. 5,9 (2021): e630. doi: https://doi.org/10.1097/HS9.0000000000000630
Beitzen-Heineke A, Berenbrok N, Waizenegger J, Paesler S, Gensch V, Udonta F, Vargas Delgado ME, Engelmann J, Hoffmann F, Schafhausen P, von Amsberg G, Riecken K, Beumer N, Imbusch CD, Lorens J, Fischer T, Pantel K, Bokemeyer C, Ben-Batalla I, Loges S. AXL Inhibition Represents a Novel Therapeutic Approach in . Hemasphere. 2021 Aug 11;5(9):e630. doi: 10.1097/HS9.0000000000000630. eCollection 2021 Sep. PMID: 34396051; PMCID: PMC8357258.
Copy Download .nbib Format: NLM
Share it on

Hemasphere. 2021 Aug 11;5(9):e630. doi: 10.1097/HS9.0000000000000630. eCollection 2021 Sep.

AXL Inhibition Represents a Novel Therapeutic Approach in .

HemaSphere

Antonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, Sarina Paesler, Victoria Gensch, Florian Udonta, Maria Elena Vargas Delgado, Janik Engelmann, Friederike Hoffmann, Philippe Schafhausen, Gunhild von Amsberg, Kristoffer Riecken, Niklas Beumer, Charles D Imbusch, James Lorens, Thomas Fischer, Klaus Pantel, Carsten Bokemeyer, Isabel Ben-Batalla, Sonja Loges

Affiliations

  1. Department for Oncology, Hematology and Bone Marrow Transplantation with the Section Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, Germany.
  2. Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  3. Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  4. Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  5. Practice for Hematology and Oncology Altona, Hamburg, Germany.
  6. Department of Stem Cell Transplantation, Research Department Cell and Gene Therapy, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  7. Division of Applied Bioinformatics, German Cancer Research Center (Deutsches Krebsforschungszentrum; DKFZ), Heidelberg, Germany.
  8. Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  9. Department of Biomedicine, Centre for Cancer Biomarkers, Norwegian Centre of Excellence, University of Bergen, Norway.
  10. BerGenBio ASA, Bergen, Norway.
  11. Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany.

PMID: 34396051 PMCID: PMC8357258 DOI: 10.1097/HS9.0000000000000630

[No abstract available.]

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

References

  1. J Hematol Oncol. 2018 Sep 24;11(1):122 - PubMed
  2. Nat Commun. 2019 Jan 16;10(1):259 - PubMed
  3. Cell. 2016 Mar 24;165(1):35-44 - PubMed
  4. Nature. 1988 Sep 29;335(6189):440-2 - PubMed
  5. Sci Signal. 2013 Aug 06;6(287):ra66 - PubMed
  6. Haematologica. 2015 Aug;100(8):1058-63 - PubMed
  7. Blood. 2018 Oct 18;132(16):1664-1674 - PubMed
  8. Haematologica. 2019 Oct;104(10):2017-2027 - PubMed
  9. N Engl J Med. 2012 Mar 1;366(9):787-98 - PubMed
  10. Blood. 2011 Feb 10;117(6):1928-37 - PubMed
  11. Front Oncol. 2020 Dec 09;10:585151 - PubMed
  12. Adv Cancer Res. 2008;100:35-83 - PubMed
  13. Mol Cancer Ther. 2018 Nov;17(11):2297-2308 - PubMed
  14. Blood. 2013 Oct 3;122(14):2443-52 - PubMed
  15. Nat Med. 2018 Feb;24(2):203-212 - PubMed
  16. Genes (Basel). 2019 Oct 15;10(10): - PubMed
  17. Clin Cancer Res. 2017 May 1;23(9):2289-2300 - PubMed
  18. N Engl J Med. 2015 Jan 29;372(5):426-35 - PubMed
  19. Cancers (Basel). 2020 Aug 23;12(9): - PubMed
  20. Cell Death Differ. 1999 Feb;6(2):99-104 - PubMed
  21. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):534-542 - PubMed
  22. Leuk Res. 2017 Sep;60:31-35 - PubMed
  23. Mol Ther. 2008 Apr;16(4):698-706 - PubMed
  24. Cancer Res. 2018 Jan 1;78(1):246-255 - PubMed
  25. Nat Commun. 2014 Dec 15;5:5712 - PubMed
  26. Blood. 2018 Nov 29;132(22):2406-2417 - PubMed
  27. EMBO J. 2012 Apr 4;31(7):1692-703 - PubMed
  28. Oncogene. 2016 May;35(21):2687-97 - PubMed
  29. Nat Genet. 2012 Jul 01;44(8):852-60 - PubMed
  30. Cell Rep. 2018 May 1;23(5):1476-1490 - PubMed
  31. Blood Cancer J. 2013 Jan 25;3:e101 - PubMed
  32. Blood. 2018 Aug 2;132(5):492-500 - PubMed
  33. Leukemia. 2011 Nov;25(11):1751-9 - PubMed
  34. Hemasphere. 2019 Jun 04;3(3):e233 - PubMed
  35. J Invest Dermatol. 2011 Dec;131(12):2448-57 - PubMed
  36. Cancer Cell. 2015 Jul 13;28(1):15-28 - PubMed
  37. Nature. 1997 Jul 17;388(6639):300-4 - PubMed
  38. Blood. 2010 Apr 15;115(15):3109-17 - PubMed
  39. Leukemia. 1999 Sep;13(9):1352-8 - PubMed
  40. Biol Open. 2015 Sep 09;4(10):1243-52 - PubMed
  41. Int J Clin Exp Pathol. 2014 Sep 15;7(10):6653-61 - PubMed
  42. JAMA Oncol. 2015 Aug;1(5):643-51 - PubMed
  43. J Clin Invest. 2008 Feb;118(2):583-96 - PubMed

Publication Types